Compare Eli Lilly And Co (LLY) vs Marriott International Inc (MAR) Price & Performance

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Marriott International (MAR) trades at $348.44, down 1.55% on the day, with a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $3.19, beating estimates, but revenue growth faces headwinds. Key risks include high debt levels and valuation concerns, while analyst consensus remains positive with a $387.31 price target.

Outlook: MAR's fee-based model and loyalty program drive growth, but elevated P/E of 36.18 and rising debt-to-asset ratio warrant caution. Upside hinges on sustained RevPAR gains and effective cost management amid global economic uncertainty.